Last update April 16, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Perindopril is also known as
Perindopril in other languages or writings:
Perindopril belongs to these groups or families:
Main tradenames from several countries containing Perindopril in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Perindopril and its active metabolite perindoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure. Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts. (Leggett 2020, Anderson 2018, Lwin 2017)
Until more published data on this drug in relation to breastfeeding are known, safer alternatives with shorter elimination times may be preferable.
Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)
The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)